$17.05
3.43% today
Nasdaq, Apr 04, 09:18 pm CET
ISIN
US7665596034
Symbol
RIGL
Sector
Industry

Rigel Pharmaceuticals, Inc. Stock price

$17.66
-4.72 21.08% 1M
+1.61 10.00% 6M
+0.84 4.96% YTD
+4.36 32.74% 1Y
-14.15 44.48% 3Y
+3.26 22.60% 5Y
-18.75 51.50% 10Y
Nasdaq, Closing price Thu, Apr 03 2025
-0.56 3.05%
ISIN
US7665596034
Symbol
RIGL
Sector
Industry

Key metrics

Market capitalization $315.37m
Enterprise Value $298.02m
P/E (TTM) P/E ratio 18.17
EV/FCF (TTM) EV/FCF 9.48
EV/Sales (TTM) EV/Sales 1.66
P/S ratio (TTM) P/S ratio 1.76
P/B ratio (TTM) P/B ratio 95.09
Revenue growth (TTM) Revenue growth 53.38%
Revenue (TTM) Revenue $179.28m
EBIT (operating result TTM) EBIT $24.19m
Free Cash Flow (TTM) Free Cash Flow $31.44m
Cash position $77.32m
EPS (TTM) EPS $0.97
P/E forward 14.20
P/S forward 1.59
EV/Sales forward 1.51
Short interest 8.97%
Show more

Is Rigel Pharmaceuticals, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.

Rigel Pharmaceuticals, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

5 Analysts have issued a Rigel Pharmaceuticals, Inc. forecast:

2x Buy
40%
3x Hold
60%

Analyst Opinions

5 Analysts have issued a Rigel Pharmaceuticals, Inc. forecast:

Buy
40%
Hold
60%

Financial data from Rigel Pharmaceuticals, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
179 179
53% 53%
100%
- Direct Costs 19 19
162% 162%
10%
161 161
46% 46%
90%
- Selling and Administrative Expenses 111 111
6% 6%
62%
- Research and Development Expense 23 23
5% 5%
13%
26 26
237% 237%
15%
- Depreciation and Amortization 2.23 2.23
78% 78%
1%
EBIT (Operating Income) EBIT 24 24
218% 218%
13%
Net Profit 17 17
170% 170%
10%

In millions USD.

Don't miss a Thing! We will send you all news about Rigel Pharmaceuticals, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Rigel Pharmaceuticals, Inc. Stock News

Positive
Seeking Alpha
22 minutes ago
Rigel Pharmaceuticals: 3-Drug Company Reaches Profitability
Neutral
PRNewsWire
about 8 hours ago
SOUTH SAN FRANCISCO, Calif. , April 4, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. ("Rigel") (Nasdaq: RIGL) today announced that it has granted awards pursuant to the Rigel Pharmaceuticals, Inc. Inducement Plan, approved by the Compensation Committee of Rigel's Board of Directors and granted as an inducement material to employees' entering into employment with Rigel, in accordance with NAS...
Neutral
PRNewsWire
8 days ago
SOUTH SAN FRANCISCO, Calif. , March 27, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it has entered into a settlement agreement with Annora Pharma Private Ltd.
More Rigel Pharmaceuticals, Inc. News

Company Profile

Rigel Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It discovers and develops novel, targeted drugs in the therapeutic areas of immunology, oncology and immune oncology. The firm focuses on intracellular signalling pathways and related targets that are critical to disease mechanisms. Its products include Tavalisse, Fostamatinib and R835. The company was founded by Donald G. Payan, James M. Gower, Thomas A. Raffin, Garry P. Nolan and Ronald B. Garren on June 14, 1996 and is headquartered in South San Francisco, CA.

Head office United States
CEO Raul Rodriguez
Employees 164
Founded 1996
Website www.rigel.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today